1. Comorbidity Medications Are Dispensed to More People Receiving Antiretroviral Therapy for HIV Compared with the General Population in Australia
- Author
-
Kathy Petoumenos, Nila J. Dharan, Prabhjot Juneja, Richard Gray, Samuel Che, Rebecca Guy, Hamish McManus, Mark N. Polizzotto, David A. Cooper, Peter Cronin, Matthew Law, Tomas Radovich, and Robin Huang
- Subjects
Adult ,Male ,medicine.medical_specialty ,Anti-HIV Agents ,Medication Therapy Management ,Immunology ,Population ,Human immunodeficiency virus (HIV) ,HIV Infections ,Sample (statistics) ,Comorbidity ,Pharmaceutical Benefits Scheme ,medicine.disease_cause ,Virology ,Humans ,Medicine ,education ,Aged ,Aged, 80 and over ,education.field_of_study ,business.industry ,Australia ,Disease Management ,virus diseases ,Middle Aged ,medicine.disease ,Antiretroviral therapy ,Infectious Diseases ,Family medicine ,Polypharmacy ,Female ,business - Abstract
Medical comorbidities occur in more persons with HIV than without HIV. We used a nationally representative 10% sample of 2016 Pharmaceutical Benefits Scheme (PBS) dispensing data to compare the proportions of antiretroviral therapy (ART)-purchasing and non-ART-purchasing patients who also purchased prescriptions for medical comorbidities. Each patient who purchased ART was compared with two gender- and age group-matched patients who did not purchase ART in the same year. We calculated the proportions of patients who also purchased coprescriptions used for hypertension, dyslipidemia, diabetes, cancer, low bone mineral density, and mental health, defined using PBS medication coding categories, and the resulting odds ratios. A total of 1,973 ART-purchasing patients in our sample were matched to 3,946 non-ART-purchasing patients. Compared with non-ART-purchasing patients, a greater proportion of ART-purchasing patients also purchased medications for dyslipidemia (19.8% vs. 16.6%
- Published
- 2020